New drug TAK-771 tested for long-term safety in immune disorder patients

NCT ID NCT05513586

First seen Nov 17, 2025 · Last updated May 13, 2026 · Updated 20 times

Summary

This study looked at the long-term safety of a drug called TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID), a condition where the immune system is weak. Participants who completed an earlier study received TAK-771 injections for up to 3 years. The main goal was to track side effects and immune reactions to the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Gifu University Hospital

    Gifu, Gifu, Japan

  • Hiroshima University Hospital

    Hiroshima, Hiroshima, Japan

  • Hospital of University of Occupational and Environmental Health

    Kitakyushu, Fukuoka, Japan

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • Nagoya University Hospital

    Nagoya, Aichi-ken, Japan

  • Saitama Prefectual Children's Medical Center

    Saitama, Saitama, Japan

  • Shizuoka Childrens Hospital

    Shizuoka, Shizuoka, Japan

  • Tokyo Medical Dental University Hospital

    Bunkyo-ku, Tokyo, Japan

Conditions

Explore the condition pages connected to this study.